Association for Molecular Pathology                       
Newsletter                                                                
   
May 2009, Volume 15, Number 2 

Inside this Issue

Front Page
President's Message
Committee Reports
• Clinical Practice Committee
• Economic Affairs Committee
• Membership & Professional  
  Development Committee

• Nominating Committee
• Professional Relations Committee
• Program Committee
• Publications Committee
• Training & Education Committee
Subdivision Reports
• Genetics
• Hematopathology
• Infectious Diseases
• Solid Tumors
Special Features
• AMP Leadership Award
• CHAMP

• Member Survey Report
• Web Editorial Board Report
• Show Me the Money!
• Announcements
• Career Opportunities
• Meetings and Upcoming Events
2009 AMP Officers and Appointees

Clinical Practice Committee Report

Iris Schrijver, MD

By Iris Schrijver, MD
Chair, Clinical Practice Committee
e-mail: ischrijver@stanfordmed.org

 

With the fruit trees blossoming and daffodils lining the freeways it is clear that Spring is in full swing, and so is the Clinical Practice Committee (CPC). We have monthly phone conferences and a myriad of initiatives and projects on which individual members work in between our calls. If you have not seen it yet, I encourage you to check out the Catalogue of Mutation Database Websites on the AMP website, which can be viewed in the “Clinical Practice Committee Comments and Projects” section of the CPC webpage (http://www.amp.org/CP/clinicalpractice.htm). One can navigate there, from www.amp.org > About AMP > Committees > Clinical Practice.

The CPC has also commented on ACMG guidelines on myotonic dystrophy; provided input on the long-range-planning white papers from the National Human Genome Research Institute (NHGRI); and created a position statement on the recommendations from the American Society of Human Genetics (ASHG) on commercial and academic ancestry testing efforts. In February, the AMP Council decided that the “AMPRCP”, a working group with members from the Public Relations Committee, the Economic Affairs Committee, and the Clinical Practice Committee, will draft a response to the Genentech Citizen Petition to FDA regarding lab-developed assays.

A working group that includes Genetics Subdivision Representatives Murali Muralidharan, and Narasimhan Nagan, and Hematopathology Subdivision Representative Dan Sabath is investigating the design of a “road map” on how AMP could proceed when payers pose questions about test utility and reimbursement. The working group is currently determining the scope of the project and the steps that should be followed when a request is received from third party payers. Hematopathology Subdivision Representative Joe Pulliam is working on a control material project for NPM1 and other cell lines for hematopathology assays.

In a project originally started by Jan Nowak, Solid Tumor Subdivision Representative Bill Funkhouser is completing the creation of a manuscript on Microsatellite Instability (MSI) testing in colon cancer. Solid Tumor Subdivision Representative Federico Monzon is exploring a new project concerning a database of validated microsatellite markers for loss of heterozygosity as well as a KRAS sample exchange.

Infectious Diseases Subdivision Representative Donna Wolk is focusing on quantitative reference materials for BK virus, whereas Belinda Yen-Lieberman is working on a project involving quantitative reference materials for CMV.

Ad hoc member Ira Lubin leads a project on the reporting of genetic test results. The journal, Genetics in Medicine, invited the working group to submit a commentary discussing the broader ramifications of the initial findings. This commentary will be authored by those who have been directly involved in past work, including Jean Amos Wilson, Elaine Lyon, and Vicky Pratt who have also been past members and Chairs of the CPC. The current CPC will provide input.

Michelle Dolan, one of our ad hoc members, is leading a project on the analytical evaluation of genotyping assays. Together with ad hoc members Fernanda Sabato and Patrik Vitazka, she is developing a practical guideline/checklist to which laboratories can refer.

And last but not least, Mary Williams is bravely fielding all our questions, capably helping to juggle all our projects, and taking terrific minutes. Our next project shall have to be an attempt to clone her. Thanks, Mary!